)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
TScan Therapeutics
TScan Therapeutics (TCRX) investor relations material
TScan Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary26 Oct, 2026
Executive summary
Special meeting set for Nov. 20, 2026, online; voting record date was Oct. 16, 2026. The board recommends FOR both proposals.
Proposal 1 seeks authority for a 1-for-2 to 1-for-50 reverse split, with the board choosing the ratio and timing; Proposal 2 would allow adjournment to solicit more votes.
Voting matters and shareholder proposals
Each proposal requires a majority of votes properly cast for or against; abstentions and broker non-votes do not affect the outcome. Brokers may vote uninstructed shares because both items are routine.
If approved, the board may implement the reverse split within one year of approval, or delay or abandon it before effectiveness; the board recommends FOR the proposal.
Adjournment authority would permit additional proxy solicitation if votes are insufficient; the board recommends FOR this proposal as well.
Rule 14a-8 proposals for the 2027 annual meeting are due by Dec. 18, 2026; other advance-notice proposals are due Jan. 20–Feb. 19, 2027.
Board of directors and corporate governance
Directors Gabriela Gruia and Garry Nicholson resigned effective Oct. 13, 2026.
Chief Financial Officer Jason Amello and Chief Medical Officer Chrystal Louis are scheduled to separate effective Nov. 1, 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from TScan Therapeutics
- A discretionary reverse split seeks to address Nasdaq’s bid-price deficiency.TCRX
Proxy filing - In vivo TCR-T solid tumor therapies advance to clinical stage, with $55M in cost savings and Q4 2027 runway.TCRXStudy update
- Net loss narrowed to $30.4M as Phase 3 trial advanced, but funding risks remain significant.TCRXQ2 2026
- Phase III trial for post-transplant relapse prevention advances with robust early efficacy and improved manufacturing.TCRXH.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- TSC-101 shows strong efficacy, safety, and market potential; pivotal Phase 3 trial is launching.TCRXKOL event
- All proposals, including director elections and share increase, were approved without opposition.TCRXAGM 2026
- Q1 2026 net loss narrowed to $28.7M, strong cash runway, and pivotal TCR-T trials set for 2026.TCRXQ1 2026
- Pivotal trial and multiplex solid tumor data expected, with expansion into new HLA types ongoing.TCRXMorgan Stanley 23rd Annual Global Healthcare Conference
- TSC100/101 cut relapse and improved survival; pivotal trial and multiplex solid tumor therapy advance.TCRXStatus Update
Next TScan Therapeutics earnings date
Q3 202618 Nov, 2026
TScan Therapeutics
Next TScan Therapeutics earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.